Phyton biotech shares new article published by iScience that demonstrates that QS-21 produced via plant cell culture for saponin-derived vaccine adjuvants can be commercially produced in a sustainable way
(March 14, 2024) Delta, British Columbia – Phyton Biotech is pleased to announce a recent publication by iScience showcasing the successful application of its plant cell fermentation platform to derive an important compound. A compound traditionally extracted from the rare Quillaja tree and used in an adjuvant for a vaccine has been successfully produced in partnership with Phyton through the application of their plant cell fermentation technology (PCF). The compound called QS-21 is another example of how Phyton continues to evolve their technology to derive needed compounds for use in sustainable commercial production.
NanOlogy Publishes Research Articles on the Immunomodulatory Effects of its Large Surface Area Microparticle Investigational Drugs
(February 14, 2024) FORT WORTH — NanOlogy LLC, a clinical-stage oncology company, announced today the publication of two research articles on anti-tumor immunomodulation associated with its investigational drugs in International Journal of Nanomedicine and Oncology and Therapy.
NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC
(December 19, 2023) FORT WORTH — Interim response and peripheral immunomodulation data from its Phase 2 clinical trial of IT LSAM-PTX in stage 3/4 lung cancer was selected for presentation during the poster discussion session during IASLC’s North American Conference on Lung Cancer. A poster reporting clinical and preclinical antitumor immunomodulation data of LSAM-DTX across multiple tumor types was presented at the Society for Immunotherapy of Cancer annual meeting.
Phyton Biotech announces acquisition of Controlled Substances Dealers License from Health Canada
(November 29, 2023) Delta, British Columbia – Phyton Biotech proudly announces a significant milestone in its journey toward advancing pharmaceutical research and development. The Company is pleased to announce the receipt of its Controlled Substances Dealers License (CSDL) from Health Canada, effective November 2023. This pivotal license empowers Phyton Biotech to engage in groundbreaking work with psilocin and psilocybin.
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung Cancer
(November 20, 2023) FORT WORTH — NanOlogy LLC, a clinical-stage oncology company, announced today that an abstract reporting interim results from its lung cancer trial has been accepted for poster presentation at the IASLC North America Conference on Lung Cancer (NACLC) being held December 1-3, 2023, at the Chicago Marriott Downtown Magnificent Mile.
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting
(October 23, 2023) FORT WORTH — NanOlogy LLC, a clinical-stage oncology company, announced today that an abstract has been accepted for poster presentation at the 38th Society for Immunotherapy of Cancer (SITC) annual meeting being held November 1-5 at the San Diego Convention Center.
Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer
(October 10, 2023) FORT WORTH, Texas–NanOlogy LLC, a clinical-stage oncology company, announced today that initial safety and clinical outcomes from a Phase 2 clinical trial of intratumoral (IT) large surface area microparticle paclitaxel (LSAM-PTX) in locally advanced pancreatic cancer (LAPC) were published online in Pancreas.
NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer
(September 12, 2023) FORT WORTH, Texas–NanOlogy LLC, a clinical-stage oncology company, announced today that two abstracts have been accepted for presentation at the ninth AACR Special Conference in Cancer Research: Pancreatic Cancer on September 27-30 in Boston, Massachusetts.
NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs
(June 7, 2023) FORT WORTH, Texas–NanOlogy LLC, a clinical-stage oncology company, announces a presentation of clinical research involving its large surface area microparticle (LSAM) investigational drugs at DDW 2023 in May and publication at ASCO Annual Meeting in June.
Phyton Biotech Abstract accepted for the Society of Economic Botany Conference
(March 15, 2023) An abstract has been accepted for presentation at the Society of Economic Botany Conference, June 4-9, 2023: Sustainable Production of Natural Substances by Plant Cell Cultivation, Gilbert Gorr, Phyton Biotech GmbH.
NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer
(March 7, 2023) — NanOlogy LLC, a clinical-stage oncology company, announced today issuance of a US patent titled: Local Delivery of Antineoplastic Particles in Combination with Systemic Delivery of Immunotherapeutic Agents for the Treatment of Cancer. The patent (11,583,499) is valid in the US until November 25, 2038, and has corresponding filings globally. It adds to an extensive global intellectual property portfolio of more than 250 issued or filed patents covering composition, formulation, use, and technology.
Phyton Biotech to Sponsor the Upcoming Economic Botany 2023 Conference
(January 12, 2023) — Phyton Biotech is a sponsor of the upcoming The Society for Economic Botany’s Economic Botany 2023 Conference.
NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts
(December 20, 2022) — NanOlogy LLC, a clinical-stage interventional oncology drug company, announced today publication of a research article entitled Early Phase Trial of Intracystic Injection of Large Surface Area Microparticle Paclitaxel (LSAM-PTX) for Treatment of Mucinous Pancreatic Cysts in Endoscopy International Open.
NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer
(November 11, 2022) – NanOlogy LLC, a clinical-stage interventional oncology drug company, announced enrollment is complete in a Phase 2a trial of intratumoral (IT) large surface area microparticle paclitaxel (LSAM-PTX) with standard of care (SOC) therapy in patients with nonoperable lung cancer.
NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX
(September 20, 2022) – NanOlogy LLC, a clinical-stage interventional oncology drug company, announced today that a review article of preclinical and clinical research supporting its investigational drug, large surface area microparticle docetaxel (LSAM-DTX), has been published in Drug Delivery and Translational Research (DDTR).
NANOLOGY announces RESULTS FROM A CLINICAL TRIAL OF LSAM-DTX IN THE TREATMENT OF high risk nonmuscle invasive bladder cancer have been published in the journal of urology
(August 1, 2022) – NanOlogy LLC, a clinical-stage interventional oncology drug company, announced today that results from a clinical trial of Large Surface Area Microparticle Docetaxel (LSAM-DTX) in High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) have been published in The Journal of Urology®.
The research article entitled Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Non-Muscle Invasive Bladder Cancer presents safety and response data from the multi-site study (NCT03636256). Clinical investigators included Max Kates, MD (Johns Hopkins Medical Institutions), Ahmed Mansour, MD (UT Health San Antonio), Donald Lamm, MD (BCG Oncology), and Neal Shore, MD (Carolina Urologic Research Institute).
Phyton Biotech Continues to Expand its Team of Scientists
(May 4, 2022) — Phyton Biotech, Ltd., a global leader in specialty fermentation solutions for naturally derived compounds and the largest global supplier of Paclitaxel and Docetaxel via Plant Cell Fermentation® (PCF), is delighted to announce that Dr. Marisol Ochoa-Villarreal has joined its team as a Scientist in the Company’s Research and Development Department.
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer
(May 3, 2022) – NanOlogy LLC, a clinical-stage interventional oncology drug company, announced today that results from a clinical trial of topical submicron particle paclitaxel (SOR007) in cutaneous metastases of breast cancer (CMOBC) have been published in Breast Cancer Research and Treatment.
The research article entitled Phase 1/2 Study of Topical Submicron Particle Paclitaxel for Cutaneous Metastases of Breast Cancer presents final safety and response data from the multi-site study (NCT03101358). Clinical investigators included Mario Lacouture, MD (Memorial Sloan Kettering Cancer Center), Julie Lang, MD (formerly USC Norris Comprehensive Cancer Center; currently Cleveland Clinic), and Sant Chawla, MD (Sarcoma Oncology Research Center).
Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care
(November 9, 2021) – NanOlogy, LLC, a clinical-stage interventional oncology drug company, announced today a single-site analysis of data from an ongoing Phase 2a clinical trial (NCT03077685) of intratumoral (IT) NanoPac® (large surface area microparticle [LSAM] paclitaxel) suspension showed improved resection rates in locally advanced pancreatic cancer (LAPC). The results were presented by Neil Sharma, MD (President, Parkview Cancer Institute, Chair, Upper GI Oncology Program, Assistant Professor, Indiana University School of Medicine) at the American College of Gastroenterology annual meeting (ACG 2021) at a plenary session on October 27, 2021. Please click on the link below to read the article.
Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions
(July 31, 2021) – NanOlogy, LLC, published above research article in Medical Oncology . Please click on the link below to read the article.
Additional Data Presented at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas
(June 9, 2021) – NanOlogy, LLC, a clinical-stage oncology company, announced today that additional data from its Phase 2 dose-rising and expansion clinical trial of intracystic NanoPac® for mucinous cystic neoplasms of the pancreas were presented via poster by Somashekar Krishna, MD, MPH of The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center during Digestive Disease Week held virtually from May 21-23, 2021. Please click on the link below to read the article.
Phyton Biotech has received Regulatory Approval from China’s NMPA for its plant cell fermentation-derived Paclitaxel Active Pharmaceutical Ingredient.
(May 25th, 2021) – Phyton Biotech is pleased to announce approval from China’s regulatory body – National Medical Products Administration (NMPA) – for Phyton’s Drug Master File for paclitaxel active pharmaceutical ingredient produced via plant cell fermentation (PCF®).
NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical Trial
(April 27, 2021) — NanOlogy, LLC, a clinical-stage interventional oncology drug therapy company, announced today the first patient has been enrolled in a clinical trial of intratumoral (IT) NanoPac®(large surface area microparticle [LSAM] paclitaxel) for suspension via endobronchial ultrasound-guided transbronchial needle injection (EBUS-TBNI) in lung cancer. A second patient is scheduled for enrollment in early May. Please click on the link below to read the article.
NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial
(March 9, 2021) — NanOlogy, LLC, a clinical-stage oncology company, today announced that enrollment has been completed in its clinical trial of NanoDoce® for bladder cancer. Please click on the link below to read the article.
Phyton Biotech Announces the Successful Establishment of Plant Cell Lines to Source Key Building Block for Treatment of Rare Dermatologic Conditions
(January 11, 2021) – Phyton Biotech today announced that it has established high-yielding plant cell lines of Veratum californicum, the source of cyclopamine, a key raw material for PellePharm’s patedigib topical gel, an investigational treatment to be used for rare dermatologic conditions. This is the first step in efforts to enable the renewable production of cyclopamine.
NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical Trial in the Treatment of Cutaneous Metastases at 2020 SABCS®
(December 29, 2020) — NanOlogy, LLC, a clinical-stage oncology company, today announced that results from its Phase 1/2 clinical trial of SOR007 (topical submicron particle paclitaxel) in the treatment of cutaneous metastases were presented during the 2020 San Antonio Breast Cancer Symposium by Mario Lacouture, MD, Director of Oncodermatology, Memorial Sloan Kettering Cancer Center. Please click on the link below to read the article.
NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer
(November 4, 2020) — NanOlogy LLC, a clinical-stage oncology company advancing intratumoral therapy for solid tumors, has enrolled the first patient in a Phase 2 clinical trial of NanoPac® (sterile nanoparticulate paclitaxel) for suspension via intratumoral injection for local prostate cancer. Please click on the link below to read the article.
Nanology LSAM-PTX review article published in Drug Delivery and Translational Research
(October 2020) — This report describes local administration of submicron particle paclitaxel (SPP) (NanoPac®: ~ 800-nm-sized particles with high relative surface area with each particle containing~ 2 billion molecules of paclitaxel) in preclinical models and clinical trials evaluating treatment of carcinomas. Paclitaxel is active in the treatment of epithelial solid tumors including ovarian, peritoneal, pancreatic, breast, esophageal, prostate, and non-small cell lung cancer. Please click on the link below to read the article.
Nanology ovarian cancer clinical trial results published in gynecologic oncology reports
(September 2020) — Nanology-sponsored clinical trial results were published in Gynecologic Oncology Reports in an article entitled: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery. The pilot study compared two concentrations of intraperitoneal NanoPac® instilled into the peritoneum of ovarian cancer patients at the end of debulking surgery. Please click on the link below to read the article.
PAUL DORMAN NAMED AGAIN TO FORT WORTH INC.’S THE 400
(July 2020) — FT WORTH, (July/August, 2020 edition) Paul Dorman, CEO of long-successful DFB Pharmaceuticals, has been named again this year as an honoree in Fort Worth Inc.’s The 400. DFB’s most recent venture is NanOlogy, a clinical-stage oncology company. Please click on the link below and turn to page 56 in the Health Care and Life Sciences Section of the digital version of the magazine to read more.
NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer
(June 2020) — FORT WORTH, NanOlogy, LLC, a clinical-stage oncology company, announced today initiation of a clinical trial of intratumoral (IT) NanoPac® (submicron particle paclitaxel) for suspension via endobronchial ultrasound-guided transbronchial needle injection (EBUS-TBNI) in NSCLC and SCLC. The trial follows FDA allowance of an investigational new drug (IND) application for IT NanoPac in neoplasms of the lung. A second IND was also allowed by FDA for a nebulized inhaled form of NanoPac in NSCLC. Five INDs have been established for NanoPac allowing progress of clinical trials via multiple routes of targeted administration for a variety of solid tumors including pancreatic, prostate, ovarian, peritoneal, and now lung.
Set up a Virtual Meeting with Phyton Biotech at Bio-Digital, June 8th – 12th
(June 2020) — VANCOUVER, BC, Phyton Biotech is excited to announce we will be participating at the upcoming Bio-Digital One-on-One Partnering Event from June 8th – 12th 2020.
Feel free to reach out to inquiries@phytonbiotech.com to schedule a meeting with us in advance!
NanOlogy Presents Updated Clinical Data on Targeted Injections of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms on DDW2020 Site
(May 2020) — FORT WORTH, NanOlogy, LLC, a clinical-stage oncology company, announced today that updated data from two of its ongoing clinical trials were presented as abstracts last week through the DDW ePosters and ePresentations site. The clinical trials are evaluating endoscopic ultrasound guided fine needle injection (EUS-FNI) of NanoPac® (submicron particle paclitaxel) suspension for treatment of locally advanced pancreatic cancer and mucinous cystic neoplasms of the pancreas.
nanology updates corporate fact sheet WITH a SUMMARY OF CLINICAL PROGRESS of its ONCOLOGY PIPELINE
(January 2020) — FORT WORTH, NanOlogy LLC, a clinical-stage oncology company, has updated its company fact sheet summarizing clinical results across its extensive pipeline. NanOlogy has developed a therapeutic drug platform designed for local delivery into solid tumors. The company has completed or is progressing clinical trials in pancreatic, peritoneal, ovarian, prostate, bladder, and renal cancers with promising signs of safety and efficacy. Click on the link below to view the fact sheet.
NanOlogy Clinical Updates on Local Injection of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasm of the Pancreas
(November 2019) — DALLAS, (November 7, 2019) NanOlogy LLC, a clinical-stage oncology company, announced today that interim data were presented last week at the 2019 ACG annual meeting from two of its clinical trials each evaluating endoscopic ultrasound guided fine needle injection (EUS-FNI) of NanoPac (submicron particle paclitaxel): one for treatment of locally advanced pancreatic cancer (LAPC) and the other for treatment of mucinous cystic neoplasms of the pancreas (MCNs).
DFB CEO Paul Dorman named bionorthTX™ 2019 Dennis K. Stone Award Recipient
(September 2019) — DALLAS, (September 3, 2019) bionorthTX™, the trade association representing the life sciences industry in North Texas, announced that Paul Dorman, entrepreneur, investor, and philanthropist, is the recipient of the 2019 Dennis K. Stone Award which recognizes an individual for his/her contributions to improving quality of life. Dorman is Chairman and CEO of DFB Pharmaceuticals, a company he cofounded in 1990 with the purchase of Dermatological Products of Texas (DPT) from Alcon Laboratories. DFB invests, develops, and operates pharmaceutical businesses that have positively impacted quality of life through the development and commercialization of life-saving drugs. With his latest venture, NanOlogy, LLC, Dorman and his team are in clinical development of a submicron particle drug platform designed for local delivery in the treatment of various cancers. Click on the link below to read the press release.
nanology inhaled nanopac® preclinical study published in JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERy
(August 2019) — FT WORTH, (August 1, 2019) The preclinical study evaluated the antineoplastic and immunostimulatory effects of inhaled submicron particle paclitaxel (NanoPac) in an orthotopic non-small cell lung cancer rodent model. Tumor regression and immune cell infiltration were observed with an increased incidence noted in animals receiving NanoPac. An IND is in process to gain FDA authorization to begin a first-in-human clinical trial in early 2020. Click on the link below to read the full article.
Paul dorman named again to fort worth inc.’s the 400
(July 2019) — FT WORTH, (July/August, 2019 edition) Paul Dorman, CEO of long-successful DFB Pharmaceuticals, has been named again this year as an honoree in Fort Worth Inc.’s The 400. Please click on the link below and turn to page 66 in the Health Care and Life Sciences Section of the digital version of the magazine to read more.
NanOlogy to Present Preclinical Lung Cancer Study Showing Inhaled NanoPac® Resulted in Increased Tumor Regression and Immune Response
(May 2019) — FT WORTH, (May 14, 2019) NanOlogy LLC, a clinical-stage oncology company, announced today that its abstract showing encouraging therapeutic effects from a preclinical pharmacology study on inhaled NanoPac® (submicron particle paclitaxel) for treatment of lung cancer has been accepted for presentation at the 2019 American Thoracic Society International Conference. The abstract, entitled Enhanced Tumor Regression and Immune Cell Infiltration by Inhaled Submicron Particle Paclitaxel in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer (NSCLC), will be presented at the conference on May 20th, 11:15 AM to 1:00 PM, during the Oncogenic Mutations, Metastases, and Novel Therapeutics poster session at the Kay Bailey Hutchison Convention Center in Dallas. Click on the link below for event information.
Nanology presentation at drug development networking summit
(April 2019) — On April 11, 2019, Marc Iacobucci, managing director of DFB-affiliate NanOlogy, speaks at the Drug Development Summit in Bridgewater, NJ on the company’s submicron particle technology platform and progress on its clinical development in oncology. Click on the link below for event information.
usa today article: Americans are excited by medical innovation — healthcare exec Paul Dorman explains why
(March 2019) — After an extraordinarily successful career as an entrepreneur and investor, storied healthcare executive Paul Dorman was all set to retire. That was until he learned about advancements in submicron particle technology and what it could mean for more effective cancer treatments. Click on the link below to read the full article.
BIO CEO & Investor Conference 2019 Panel video
(February 2019) — NanOlogy chief medical officer, Gere diZerega, MD, participated in a panel discussion on “Reshaping Tumor Microenvironments via Immunotherapies” at the 2019 BIO CEO & Investor Conference in New York.
Nanology named as one of the Top 20 Life Science Startups to Watch in 2019
(January 2019) — NanOlogy was named as one of the top 20 life science start ups to watch in 2019 by BioSpace Inc., a leading digital news publication in life sciences and biotechnology.
dorman among 13 people in fort worth to watch in 2019
(January 2019) — Fort Worth Magazine named DFB Chairman and CEO, H. Paul Dorman, was one of 13 Fort Worthians to watch in 2019 based on progress of NanOlogy, a clinical-stage oncology company, he founded in 2015.
WuXI apptec article featuring ceo h. paul dorman: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy
(November 2018) — NanOlogy CEO, H. Paul Dorman, had an opportunity to speak with WuXi Apptec, a leading development services and communication business with focus on China, on the combination of chemotherapies and immunotherapies to highlight the significance of small molecule drug development as an ongoing treatment modality. Click on the link below to read the full article.
Drug development & delivery article - Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm
(September 2018) — NanOlogy published an article in the September issue of Drug Development with an update on its extensive preclinical and clinical development programs across three therapeutic areas and nine indications in cancer and related conditions. The company has now generated data on local delivery of its investigational drugs that are showing evidence of significant tumor reduction without the side effects associated with systemically administered chemotherapeutic agents. As importantly, the drugs are eliciting a strong immune response that may help sensitize the newer immunotherapies to increase their value in the treatment of cancer. Click on the link below to read the article.
DFB Soria Completes a Phase 2 Clinical Trial of Submicron Particle Paclitaxel Anhydrous Ointment for Actinic Keratosis
FT. WORTH/DALLAS, (September 18, 2018) — DFB Soria, a DFB Pharmaceuticals company, today announced completion of a dose-rising clinical trial of a topically applied submicron particle paclitaxel suspended in a pharmaceutically elegant, preservative-free anhydrous base. The trial was designed to evaluate safety and preliminary efficacy of four strengths of the product applied twice daily for 28 days. Results from the trial show evidence of AK lesion reduction in size and count, dose response, and minimal local irritation or other side effects.
NanOlogy™ presents preclinical lung data on nanopac® at ASCO Annual meeting in june
FT. WORTH/DALLAS, (June 15, 2018) — NanOlogy LLC, a clinical-stage pharmaceutical development company, presented data at the ASCO Annual Meeting in June from preclinical studies of inhaled NanoPac (submicron particle paclitaxel) showing prolonged retention of drug in lung tissue and significant tumor regression without adverse drug-related observations in an orthotopic animal model of non-small cell lung cancer (NSCLC). Click on the link below to view the abstract.
NanOlogy™ Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
FT.WORTH/DALLAS, (April 30, 2018) — NanOlogy LLC, a clinical-stage pharmaceutical development company, has completed the dose escalation phase of an open-label clinical trial of NanoPac (submicron particle paclitaxel sterile suspension) injected directly into the tumor area for treatment of prostate cancer. Successful completion of the dose escalation phase has allowed the highest concentration of NanoPac to begin the dose confirmation phase of the trial, which will continue to generate data on safety and tumor response.
Drug development & delivery EXECUTIVE INTERVIEW - NanOlogy: Submicron Particle Platform Transforms Systemic Chemotherapy Into Local Delivery
(March 2018) — Demand for new cancer drugs is enormous with public and private investment skyrocketing for the latest technologies. Immuno-oncology therapies have captured much of the attention, and much of the investment, in recent years. The first generation of these drugs has offered some breakthroughs but not a panacea; and development of more effective, safer, and cost-effective therapies is still years away. Moreover, in patients for which immuno-oncology agents are indicated, oncologists frequently combine their use with traditional chemotherapeutics. Such combination use has been found to be synergistic but also, unfortunately, additive in systemic side effects. In the near term, increasing the safety and effectiveness of proven chemotherapies, such as paclitaxel and docetaxel, have the potential to improve the outlook for cancer patients much more quickly and cost-effectively. NanOlogy LLC, a clinical-stage pharmaceutical development company, is attempting to do just that by utilizing a breakthrough technology for producing unique, patented, naked submicron particles of paclitaxel and docetaxel.
NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial for Cutaneous Metastases and DFB Soria Provides an Update on AK Trial
DALLAS/FT.WORTH, (February 14, 2018) — NanOlogy LLC, a clinical-stage pharmaceutical development company and affiliate of DFB Pharmaceuticals, today announced enrollment of the first patient in a Phase 1/2 clinical trial of a submicron particle paclitaxel topical anhydrous ointment for the treatment of cutaneous metastases. The open label dose escalating trial of three different strengths of the product will be followed by dose confirmation to evaluate safety and preliminary safety. NanOlogy has licensed the topical formulation for use in oncology from DFB Soria, which is owned and operated by DFB.
Next-Generation Nanomedicines article in pharmavoice
(January 2018) — NanOlogy LLC, managing director, Marc Iacobucci, speaks to PharmaVOICE about nanomedicines and how the company is using nanotechnology to transform the treatment of cancer.
Phyton Biotech Unifies International Operations Under New Leadership
VANCOUVER, BC (December 21, 2017) —DFB announces the promotion of Colin Marr to President of Phyton Biotech, the world’s leader in commercial-scale plant cell fermentation technology and DFB’s wholly-owned subsidiary.
NanOlogy™ Announces First Patient Enrolled in a Pancreatic Cancer Phase 2 Clinical Trial of NanoPac® Adding to Trials in Prostate and Ovarian Cancers
DALLAS/FT.WORTH, (December 18, 2017) — NanOlogy LLC, a clinical-stage pharmaceutical development company, today announced the first patient has been enrolled in a clinical trial of NanoPac® (nanoparticle paclitaxel) sterile suspension administered intratumorally in patients with locally advanced pancreatic adenocarcinoma. The Phase 2a dose-rising trial will evaluate the safety and preliminary efficacy of NanoPac delivered directly into the tumor by endoscopic ultrasound-guided fine needle injection in patients who have completed current standard of care treatment prior to trial entry. NanoPac is part of an extensive submicron technology platform developed by NanOlogy. Gere diZerega, MD, VP of Medical Affairs, will present an overview of the platform and an update of the clinical program at Biotech Showcase™, on January 8, 2018 at 3:45PM in Franciscan room D (Ballroom Level) of the Hilton San Francisco Union Square.
Phyton Biotech Wins Grant from Bill & Melinda Gates Foundation to Develop New Approaches to Manufacturing Artemisinin Pancreas
AHRENSBURG, Germany, (November 29, 2017) — Phyton Biotech today announced that it has received a $400,000 grant from the Bill & Melinda Gates Foundation to fund the research and development of an alternative method of producing artemisinin, a key active pharmaceutical ingredient (API) used to combat malaria. Artemisinin-based therapies are the global standard for the treatment of malaria, a disease that affects over 200 million people annually and is on the rise. The API is derived from the leaves of the herb Artemisia annua or sweet wormwood, a plant that is primarily harvested in Asia for the critical drug ingredient. With demand expected to continue to grow over the next twenty years, alternative methods of commercially producing the vital drug ingredient will be needed to ensure adequate, sustainable supply and stable prices.
NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Mucinous Cysts of the Pancreas
DALLAS/FT.WORTH, (November 7, 2017) — NanOlogy LLC, a clinical-stage pharmaceutical development company, today announced the first patient has been enrolled in a clinical trial of NanoPac® (nanoparticle paclitaxel) sterile suspension for treatment of mucinous cystic neoplasms (MCNs) of the pancreas. The Phase 2 dose-rising trial will evaluate the safety and preliminary efficacy of NanoPac delivered directly into MCNs by endoscopic ultrasound-guided fine needle injection.
NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
DALLAS/FT.WORTH, (October 16, 2017) — NanOlogy LLC, a clinical-stage pharmaceutical development company, today announced the first patient has been enrolled in a clinical trial of NanoPac® (nanoparticle paclitaxel) sterile suspension administered into the prostate for treatment of prostate cancer. Part of a broad nanoparticle technology platform developed by the company, NanoPac will be evaluated for safety and preliminary efficacy in a dose-rising Phase 2(a) clinical trial following intratumoral injection of the prostate via transrectal ultrasound guidance in patients four weeks prior to radical prostatectomy.
NanOlogy™Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Ovarian Cancer
DALLAS/FT.WORTH, (October 9, 2017) —NanOlogy LLC , a clinical-stage pharmaceutical development company, today announced enrollment of the first patient in a Phase 2 clinical trial of intraperitoneally (IP) administered NanoPac® (nanoparticle paclitaxel) sterile suspension in patients with ovarian cancer. Part of a broad nanoparticle technology platform developed by the company, NanoPac will be evaluated for safety and efficacy after IP instillation of NanoPac at the end of cytoreductive (debulking) surgery.
NanOlogy™ to present at Bio investor forum on October 17, 2017 in san Francisco
DALLAS/FT.WORTH, (September 26, 2017) —NanOlogy™, a clinical-stage pharmaceutical development company, announced today that VP of Medical Affairs Gere diZerega, MD, will present at the BIO Investor Forum conference Tuesday, October 17 at 9:45 am at the Westin St. Francis in San Francisco. The presentation will cover the status of the company’s clinical development program and how its nanoparticle technology platform aims to transform systemic chemotherapy into local delivery of proven drugs.
DFB Soria gives update on enrollment of phase 2 clinical trial of sor007 (nanoparticle paclitaxel) ointment for actinic keratosis (AK)
DALLAS/FT.WORTH, (September 26, 2017) —DFB Soria, a clinical-stage pharmaceutical development company, and an affiliate of NanOlogy™, today announced completion of the second of four patient cohorts enrolled in a Phase 2 actinic keratosis (AK) clinical trial of a topical ointment containing nanoparticle paclitaxel formed by a proprietary production process. Identified as SOR007, the ointment is being evaluated topically in a dose escalating trial for safety and preliminary efficacy.
drug development and delivery article on formation of NanOlogy & Soria for Clinical Development of Naked Nanoparticle Platform
September 14, 2017 – Demand for new cancer drugs is enormous with public and private investment skyrocketing for new technologies. Immunotherapies have captured much of the attention in recent years, but the first generation of these drugs has not delivered the hoped for panacea and development of more effective, safer immunotherapies is still years from reaching patients. In addition, immunotherapy is extremely expensive with treatment costs easily reaching $100,000 or more annually per patient.
DFB Pharmaceuticals Forms NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses
September 12, 2017 – DFB Pharmaceuticals, a private investment and development group, in collaboration with CritiTech and US Biotest, has formed NanOlogy to finance and develop a breakthrough technology platform to produce unique, patented, naked nanoparticle forms of paclitaxel and docetaxel for local delivery with the potential for greater efficacy and safety to treat cancer and other serious illnesses.
Texas Wesleyan and partners to honor Dorman at 48th Business Hall of Fame
July 7, 2017 – Texas Wesleyan University, the Fort Worth Business Press and the Fort Worth Chamber of Commerce are pleased to announce that Paul Dorman, CEO and chairman of DFB Pharmaceuticals, LLC, has been selected as the 2017 Fort Worth Business Executive of the Year.
Fort Worth entrepreneur, business executive provides tuition scholarships for new M.D. school
April 18, 2017 – In a show of support for the new TCU and UNTHSC School of Medicine, Fort Worth pharmaceutical executive, business investor and entrepreneur Paul Dorman will provide full first-year tuition to the inaugural class of medical students.
smith & nephew to acquire us bioactive wound care business for $782 million
November 28, 2012 – Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, today announces that it is strengthening its global position in advanced wound care by entering into an agreement through its subsidiaries to acquire substantially all the assets of Healthpoint Biotherapeutics (“Healthpoint”), a leader in bioactive debridement, dermal repair and regeneration wound care treatments, for $782 million in cash.
Roundtable healthcare partners portfolio company, renaissance acquisition holdings, LLC Acquires dpt Laboratories
LAKE FOREST, IL, July 5, 2012 — RoundTable Healthcare Partners (“RoundTable”), an operating‐oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company, Renaissance Acquisition Holdings, LLC (“Renaissance”), has acquired DPT Laboratories Inc. (“DPT”).